key: cord-1054544-y0ruhzmg
authors: Goffin, Emeline; Hemmi, Silvio; Machiels, Bénédicte; Gillet, Laurent
title: A single oral immunization with a replication-competent adenovirus-vectored vaccine protects mice from influenza respiratory infection
date: 2021-07-21
journal: bioRxiv
DOI: 10.1101/2021.07.21.453241
sha: 89cc83959520f6d9d839a264afa69bb230127745
doc_id: 1054544
cord_uid: y0ruhzmg

The development of effective and flexible vaccine platforms is a major public health challenge as recently highlighted by the COVID-19 pandemic. Adenoviruses (AdVs) are easy to produce and have a good safety and efficacy profile when administered orally as demonstrated by the long-term use of oral AdV 4 and 7 vaccines in the US military. These viruses therefore appear to be the ideal backbone for the development of oral replicative vector vaccines. However, research on these vaccines is limited by the ineffective replication of human AdVs in laboratory animals. The use of mouse AdV type 1 (MAV-1) in its natural host allows infection to be studied under replicative conditions. Here, we orally vaccinated mice with MAV-1 vectors expressing the full length or the “headless” hemagglutinin (HA) of influenza to assess the protection conferred against an intranasal challenge of influenza. We showed that while the headless HA vector did not generate a significant humoral or cellular immune response to influenza, a single oral immunisation with the full-length HA vaccine generated influenza-specific and neutralizing antibodies and completely protected the mice against clinical signs and viral replication. Importance Given the constant threat of pandemics and the need for annual vaccination against influenza and possibly emerging agents such as SARS-CoV-2, new types of vaccines that are easier to produce and administer and therefore more widely accepted are a critical public health need. Here, using a relevant animal model, we have shown that replicative oral AdV vaccine vectors can help make vaccination against major respiratory diseases more available, better accepted and therefore more effective. These results could be of major importance in the coming years in the fight against emerging diseases such as COVID-19.

Introduction 7 C). These results indicate that the MAV-1 FL HA vaccine completely protected against lung 161 inflammation consecutive to influenza respiratory challenge. This protection against influenza seems 162 to not rely on lung cellular innate immunity or on specific CD8 T cells. On the contrary, oral 163 administration of the MAV-1 HL HA vector did not protect against lung inflammation caused by an 164 influenza challenge. 165

Finally, we evaluated the protection against influenza replication in the lung. For this purpose, 166 we titrated the virus in the lung tissue by plaque assay one week post-sublethal challenge (Fig. 7A) . 167 We detected high amounts of influenza viruses in the mock/PR8, MAV-1 WT/PR8 and MAV-1 HL 168 HA/PR8 groups, though the levels tended to be lower in this last group. In contrast, in the MAV-1 FL 169 HA /PR8 group, no PR8 virus was detected (Fig. 7B) . These results show that, while the MAV-1 HL 170 HA fails to prevent influenza replication in the lung, the MAV-1 FL HA vaccine fully protects against 171 respiratory infection and viral replication. 172

The development of influenza vaccines is a major public health issue (22) . While the 174 identification of conserved antigens is a priority in order to improve the efficacy of vaccines in the 175 face of seasonal variations of the virus (23, 24), the development of new routes of administration 176 seems equally important in order to broaden the adherence of target populations and facilitate the 177 organisation of vaccination campaigns (4, 25) . Indeed, in light of the COVID-19 crisis, it appears that 178 economic and logistical considerations can crucially impact the deployment of vaccination at the 179 worldwide scale (26). 180

Here we established a mouse model to study and evaluate replication-competent AdV-vectors 181 as oral vaccine platforms for influenza, and potentially for other infectious respiratory diseases such as 182 the one caused by SARS-CoV-2. To this end, we constructed recombinant MAV-1 expressing either 183 the FL or the HL HA of the mouse adapted strain of influenza PR8. Our results showed that MAV-1 184 replication competent AdV vector expressing the FL HA was able to elicit a potent specific and 185 neutralizing systemic antibody response associated with full protection against a lethal influenza 186 challenge. In contrast, the same vector expressing HL HA, which is described as a "universal" 187 influenza antigen (7, 27) failed to generate any detectable protection or immune response against 188 influenza. Oral administration of MAV-1 FL HA vaccine completely prevented mortality, weight loss 189 or other visible signs of disease, and inhibited lung viral replication. Our results suggest that the 190 protection observed mainly relies on systemic antibodies which would transude through the respiratory 191 mucosa and block virus entry so efficiently that no other immune response is required. In accordance 192 with these results, the absence of viral replication detected by plaque assay on lung tissue one week 193 after the challenge suggests sterile immunity. Although earlier time-points should be tested to confirm 194 these results, that level of immunity would constitute a substantial benefit, since it could allow 195 breaking of the transmission chain. It is notable that an oral virus vectored vaccine triggers so strong a 196 systemic humoral immune response, because oral administration is first expected to induce local 197 mucosal immunity (28). The level of serum antibodies is considered as the gold standard correlate of 198 protection for influenza (29-31) and many other diseases (32, 33). The ability to induce such high 199 levels of specific antibody in serum is thus promising for further vaccine evaluation and development, 200 as well as for epidemic or pandemic management (34). 201

In contrast, the HL HA vaccine did not generate any significant immune protection. 202

Considering that most epitopes involved in the protective neutralizing antibody response are contained 203 in the globular head (35), a less efficient immune response was expected with this antigen (23, 36). A 204 previous study using HL HA in a vaccine regimen based on two injections of DNA plasmid vector, 205 followed by one injection of Freund adjuvanted VLP, showed that this antigen was able to give rise to 206 specific and neutralizing antibodies cross reacting against different influenza subtypes (7). However, 207 that humoral response was only observed in some recipient mice, while others did not respond. We 208 postulated here that a replication competent AdV oral vaccine vector could potentially improve the 209 efficiency of the HL HA based vaccination strategy by allowing in vivo amplification of the antigenic 210 transgene and stimulating mucosal immunity (37). However, these theoretical advantages were refuted 211 by our results. 212 Surprisingly, after influenza virus challenge, total CD8 T cells and HA stalk domain specific 213 CD8 T cells were significantly higher in the WT MAV-1 and HL HA MAV-1 groups than in the mock 214 group ( Fig. 5C and 6C ). This suggests that the vector itself contributed to the development of a 215 specific cytotoxic response and illustrates the potential ability of AdV vectors to enhance immunity 216 against a heterologous challenge and to orientate it toward CD8 T cell response. This better CD8 217 response also seemed to correlate with lower lung viral load (Fig. 7) . A similar boost of heterologous 218 immunity was recently made in the context of other viral infections by our group (38). Considering 219 these observations, development of vectored-vaccines based on replication competent AdVs could also 220 be advantageous for an improved T cell immune response. Cellular immunity to influenza raises 221 growing interest in the field of universal influenza vaccine researches (24, (39) (40) (41) . T antigens endure 222 less immune pressure than B antigens and should be more conserved for different influenza strains. 223

Several studies suggest that cytotoxic response could provide at least partial protection (42, 43). Since 224 our HL HA vaccine was not efficient, other antigens known to trigger a good cytotoxic response could 225 be considered. For example, influenza nucleoprotein specific CD8 + T cells partially prevent influenza 226 mortality in mice (40). 227

Finally, recently AdV vectors have emerged as powerful weapons to oppose to the SARS-228

CoV-2 pandemic. The worldwide use of these platforms to control COVID-19 confirms and supports 229 the feasibility of AdVs for immunization against other infectious diseases, particularly influenza. 230

These vaccine platforms are indeed efficient and easy to adapt and produce. Moreover, as compared to 231 mRNA technologies, they are cheaper, and their conservation does not necessitate extremely low 232 temperatures. However, AdV based vaccines remain optimisable. In that regard, the use of replication 233 competent vectors through the oral route could offer critical improvement in production, distribution, 234 and administration, thus contributing to vaccine access and equity. Furthermore, needle free 235 administration would certainly help to overcome vaccine hesitancies. Finally, from an immunological 236 point of view, the potential to confer sterile immunity would allow attaining herd immunity faster. 237

In this study, we showed in a mouse model that an oral replicative AdV based vaccine 238 provided complete protection against a lethal respiratory challenge without generating any detectable 239 adverse effect. Although these encouraging results were obtained with a highly immunogenic antigen 240 and a perfectly homologous challenge, they encourage the study of replicating AdVs as vectors for the 241 development of oral vaccines against influenza or other respiratory diseases, including Several studies have investigated the potential of replication-competent AdV oral vaccine vectors, 243 notably against influenza (44-46). However, those researches generally used human AdV in animals, 244

i.e., in non-replicative conditions, which limits applicability of results in terms of animal to human 245 translation. Phase I studies have also been done in humans, but oral AdVs were only used in 246 combination with intramuscular inactivated seasonal vaccine boost (47). To our knowledge, an animal 247 model allowing study of replication competent AdV vaccine vectors in a permissive host, such as 248 MAV-1 in mouse, has been studied to date (19, 48) . This work establishes an original and useful tool 249 to better evaluate AdV vaccine platforms in vivo. This opens new possibilities for preclinical 250 evaluation of replication competent AdV vectors in terms of safety and efficacy. Reliable animal 251 models are needed to provide sound data on the risks and benefits associated with new generation 252 vaccine platforms, so that these technologies can be used in an informed manner when an emergency 253 requires rapid responses. 254

Animals. All animal work complied with relevant European, federal, and institutional policies. The 256

Committee on the Ethics of Animal Experiments of the University of Liège reviewed and approved 257 the protocol (permit number 1526). Female BALB/c mice were purchased from Envigo. All mice were 258 housed in the University of Liège, Department of Infectious Diseases. The animals were infected 259 orally or intranasally with MAV-1 or PR8 influenza, when 7-8 and 11-13 weeks old, respectively. Antifade Mountant (ThermoFisher) on glass plates. Z-stack images were taken using the Leica SP5 337 confocal microscope and compiled using ImageJ Software (56). 338

Quantification of PR8 specific antibodies by in-cell ELISA. 3T6 cells were plated in 96-well 339 plates at 5x10 3 cells per well, infected with 500 TCID 50 of MAV-1 per well, and incubated at 37°C, 340 5% CO 2 . When cytopathic effect was observed (approximately 5 days p.i.), cells were fixed in 2% 341 paraformaldehyde for 20 min at RT, washed 2 times in PBS and blocked for 30 min with PBS, 10% 342 FCS, 300 mM glycine. Cells were then incubated at 4°C for 2 h with mouse sera diluted 100-fold in 343 the blocking solution. Cells were washed 3 times in PBS and incubated at room temperature for 30 344 min with a goat anti-mouse Ig polyclonal secondary antibody conjugated with alkaline phosphatase 345 (0.5 µg/mL, Sigma). After 3 washes with PBS, p-nitrophenyl phosphate (Sigma) was added and 346 incubated for one hour, then the reaction was stopped with 1M sodium hydroxide. Absorbance was 347 measured at 405 nm using a benchmark ELISA plate reader (Thermo). Signals detected from mock 348 infected cells were used as background and this background was subtracted from the corresponding 349 values obtained with MAV-1-infected wells. 350

In vivo samples collection and processing. Mice were euthanized by isoflurane inhalation. After 351 euthanasia, the trachea was catheterized and BAL was performed by 2 consecutive flushes of the lungs 352 with 1 mL ice-cold PBS containing Complete Protease Inhibitor Cocktail (Roche). Cell density in 353 BAL fluid (BALF) was evaluated using a hemocytometer after Tuerk solution staining (Sigma-354 Aldrich). Differential cell counts in BALF were determined by flow cytometry analysis. For lung 355 tissue and cells suspension preparations before plaque assay and FACS analysis, lungs were perfused 356 with ice-cold PBS through the right ventricle. Then, lung lobes were collected into a C-Tube 357 (Miltenyi) containing complete HBSS medium, 1 mg/mL collagenase D (Roche) and 50 µg/mL DNase 358 I (Roche), processed with a gentleMACS dissociator (Miltenyi). One third of this homogenate was 359 kept at -80°C to be titrated latter; the remaining two-thirds were incubated for 30 min at 37°C, then µm filter. Cell density was evaluated using a hemocytometer after Tuerk solution staining (Sigma-362 Aldrich). Differential cell counts in lung parenchyma were determined by flow cytometry analysis. 363

containing 2 mM EDTA, 0.5% BSA and 0.1% NaN3) at 4°C. Cells were first incubated for 20 min 365 with a purified rat IgG2a anti-mouse CD16/CD32 antibody (1/500) to block Fc binding. FACS 

Kendig's Disord Respir Tract Child 460-465.e2

Structure of the 419 influenza virus haemagglutinin complexed with its receptor, sialic acid

Structure of the catalytic and antigenic sites in 421 influenza virus neuraminidase

Prevention and Control of Seasonal Influenza with Vaccines

Broadly protective influenza 427 vaccines: design and production platforms

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

Innovative Mucosal Vaccine Formulations Against Influenza A 432 Virus Infections

Current state and challenges in developing 434 oral vaccines. Adv Drug Deliv Rev2017/04/26

Prospects for oral replicating adenovirus-vectored vaccines

Quadrivalent Influenza Vaccine in Ferrets and Mice

Oral administration of an adenovirus vector encoding both an 449 avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and 450

IFN-gamma T cell responses in humans. Vaccine2013/01/30

An adenovirus-based 452 vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian 453 influenza in oral delivery models. Clin Vaccine Immunol2012/11/17

Abortive adenovirus infection and host range determinants

The role of mouse adenovirus type 1 early region 1A 457 in acute and persistent infections in mice

Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the 460

Viral Vaccine beyond the Gastrointestinal Tract

Mouse Adenovirus Type 1 Early

Region 1A Effects on the Blood-Brain Barrier

Novel immunocompetent murine tumor model for evaluation of conditionally

Universal epitopes of influenza virus hemagglutinins

Recent progress in mucosal vaccine development: potential and limitations

Correlates of protection to influenza virus, where do we go from here? Hum 481

Novel correlates 484 of protection against pandemic H1N1 influenza A virus infection

Updates on immunologic correlates of vaccine-induced protection

Correlates of Protection Induced by Vaccination

Serology assays to manage COVID-19

Targeting B cell responses in universal influenza 495 vaccine design

Development of next generation hemagglutinin-based broadly 497 protective influenza virus vaccines

Prospects for oral replicating adenovirus-vectored vaccines

AM, alveolar macrophages; Neutro, neutrophils; MO, monocytes

FIG 5 Characterization of lung parenchyma immune cell populations after HL HA MAV-1 and FL 592

HA MAV-1 oral immunization and influenza PR8 respiratory challenge. (A) Eight-week-old female 593

At 28 days post-immunization, mice were challenged or not by intranasal 595 administration of 25 PFU of PR8 influenza

Representative flow cytometry dot plots (B) and total numbers (C) of immune cell populations in 597 lung parenchyma

001 (one-way ANOVA and Bonferroni post-tests). AM, alveolar macrophages

FIG 6 Quantification of lung parenchyma influenza specific CD8 + T cells. (A) Eight-week-old 601

At 28 days post-immunization, mice were challenged or not by 603 intranasal administration of 25 PFU of PR8 influenza. Mice were euthanized at day 7 after intranasal 604 challenge. Representative flow cytometry dot plots (B) and total numbers (C) CD8 + T cells and of 605 effector memory influenza specific CD8 + T cells in lung

001 (one-way ANOVA and Bonferroni post-tests). T EM cells, 608 effector memory T cells; Tetra, Influenza A HA tetramer positive cells

FIG 7 Quantification of influenza PR8 titres in lungs after HL HA MAV-1 and FL HA MAV-1

Eight-week-old female BALB/c mice 611 were orally immunized with 10 4 TCID50 of WT, HL HA or FL HA MAV-1 or with PBS as a control 612 (mock)

PFU of PR8 influenza. Mice were euthanized at day 7 after intranasal challenge. (B) Numbers of PR8 614